Full-Time
Posted on 11/13/2024
Biotech company developing innovative medicines
$170k - $186.2kAnnually
Senior, Expert
San Bruno, CA, USA + 1 more
More locations: Hayward, CA, USA
Positions will be moving from Hayward, CA to Millbrae, CA starting April 2025.
You match the following Eikon Therapeutics's candidate preferences
Employers are more likely to interview you if you match these preferences:
Eikon Therapeutics develops new medicines in the pharmaceutical industry by studying biological systems to identify drug targets. They utilize a proprietary single-molecule tracking platform to visualize protein movements in living cells, combined with artificial intelligence and automation for precise analysis of molecular interactions. Their diverse team integrates science and engineering to create therapies aimed at improving the lives of patients with serious diseases. The company's goal is to leverage advanced technologies to address unmet medical needs.
Company Size
201-500
Company Stage
Series C
Total Funding
$750.8M
Headquarters
Hayward, California
Founded
2019
Help us improve and share your feedback! Did you find this helpful?
401(k) Company Match
Medical (premiums covered by Eikon at 95%)
Dental Insurance
Vision Insurance
Mental Health Support
Unlimited Paid Time Off
Paid Holidays
Life Insurance
Enhanced Parental Leave
Daily subsidized lunch program
Eikon Therapeutics to present at the 43rd Annual J.P. Morgan Healthcare Conference.
Eikon Therapeutics announces appointment of Michael klobuchar as Chief Operating Officer.
Have you ever heard of a biotech unicorn? Although a mythological creature might be what first springs to mind, a unicorn in the business world actually refers to a privately owned company valued at more than $1 billion. Some world-renowned former unicorns include Airbnb, Facebook, and Google. The reason they are called “unicorns” is because it is traditionally very rare for a company to achieve this valuation.In the biotech world, there are only a select few companies with unicorn status that are working on therapeutics. In this article, we take a closer look at 12 biotech unicorns rated in order of their valuations according to CB Insights.Table of contentsAbogen BiosciencesAbogen Biosciences is a Chinese biotech company and is valued at $3.7 billion. This comes as no surprise after it raised $700 million in series C funding back in August 2021, marking one of the largest private biotech funding rounds ever and obliterating the fundraising record for a Chinese mRNA vaccine developer. It then followed this round with another impressive series C+ round in November of the same year, in which it raised $300 million.Abogen is part of a rare breed of Chinese biotechs, having actually developed all of its key messenger RNA (mRNA) platform technologies itself, across mRNA synthesis, delivery, and manufacturing
Cushman & Wakefield said Tuesday that it arranged three new long-term leases and one lease renewal totaling 62,131 square feet at 3 Second St., a 600,000-square-foot Class A office tower in Jersey City.Hyundai Motor America signed a 12,580-square-foot lease on the fifth floor.In addition, Eikon Therapeutics signed a 36,284-square-foot lease on the fourth floor. Bank of Montreal renewed its 10,365-square-foot lease on the 12th floor. And Arco Design/Build signed a 2,902-square-foot lease on the eighth floor.Cushman & Wakefield’s David DeMatteis, Robert Rudin, Mina Shehata and Dirk Hrobsky represented the landlord, funds managed by Ares Management, in the transactions. William O’Keefe, Raymond Trevisan and Don Yahn, also of Cushman & Wakefield, represented Hyundai.“We are thrilled to welcome new tenants and to expand relationships with existing ones to enhance 3 Second St.’s impressive tenant roster,” DeMatteis said. “These leases are further evidence that the best located, highly amenitized buildings attract tenants. The Ares Management Real Estate Group has provided a hands-on approach to ownership and is constantly reinvesting in this asset with hospitality-focused upgrades, including a new, thoughtfully designed tenant sky lounge that is currently underway.”3 Second St
Disclaimer: You are now leaving PharmiWeb.com website and are going to a website that is not operated by us. We are not responsible for the content or availability of linked sites. ABOUT THIRD PARTY LINKS ON OUR SITE. PharmiWeb.com offers links to other third party websites that may be of interest to our website visitors. The links provided in our website are provided solely for your convenience and may assist you in locating other useful information on the Internet. When you click on these links you will leave the PharmiWeb.com website and will be redirected to another site
Eikon Therapeutics announces the election of Robert L. Huffines to its Board of directors.
Eikon Therapeutics, Inc., a biotechnology company that is advancing breakthrough therapeutics through the purposeful integration of engineering and sc
Impact Therapeutics entered into global partnership with Eikon Therapeutics to develop and commercialize PARP1 selective inhibitors.
IMPACT Therapeutics and Eikon Therapeutics have recently announced a global license and collaboration agreement for the development of PARP1 selective inhibitors, including IMP1734.
Under the leadership of Roy Baynes, experienced team of industry veterans is poised to successfully move assets through clinical development and regulatory reviewHAYWARD, Calif.--(BUSINESS WIRE)-- Eikon Therapeutics, Inc., a clinical stage biotechnology company that is advancing breakthrough therapeutics through the purposeful integration of engineering and science, today announced its Clinical Development organization. Under the leadership of Roy Baynes, M.D., Ph.D., Chief Medical Officer of Eikon, this team of experienced industry professionals will be responsible for every stage of clinical development and accelerating the company’s lead pipeline candidates into and through trials and regulatory review. Eikon recently announced its development pipeline, which includes a number of acquired clinical and preclinical stage assets that complement its discovery-stage programs.“In support of our vision to build a global biotechnology company focused on developing important new medicines, we have recruited a sophisticated team of industry experts who have decades of collective experience in managing every component of advancing new drug candidates from their earliest stages through the clinic to regulatory approval,” said Roger M. Perlmutter, M.D., Ph.D., CEO and Board Chair of Eikon Therapeutics. “This team is fully integrated within our organization and is working alongside our advanced engineering and research team, who have dramatically accelerated the performance of our pioneering Single Molecule Tracking (SMT) technology. Together, they position Eikon to become a fully integrated global biotechnology company.”Baynes added, “I am incredibly proud of the team we are building here at Eikon